

Title (en)  
PARAPHARMACEUTICAL OR PHARMACEUTICAL COMPOSITION ADMINISTRABLE TO A LIVING BEING, PREFERABLY A HUMAN BEING, COMPRISING AT LEAST ONE ENZYME FOR THE TREATMENT AND/OR PREVENTION OF BACTERIAL INFECTIONS INVOLVING BIOFILM FORMATION

Title (de)  
PARAPHARMAZEUTISCHE ODER PHARMAZEUTISCHE ZUSAMMENSETZUNG FÜR LEBEWESSEN, VORZUGSWEISE FÜR BIOFILM

Title (fr)  
COMPOSITION PARA-PHARMACEUTIQUE OU PHARMACEUTIQUE ADMINISTRABLE À UN ÊTRE VIVANT, DE PRÉFÉRENCE UN ÊTRE HUMAIN COMPRENANT AU MOINS UNE ENZYME POUR LE TRAITEMENT ET/OU LA PRÉVENTION D'INFECTIONS BACTÉRIENNES IMPLIQUANT LA FORMATION DE BIOFILM

Publication  
**EP 4228678 A1 20230823 (FR)**

Application  
**EP 21797993 A 20211018**

Priority  
• BE 202005726 A 20201016  
• EP 2021078824 W 20211018

Abstract (en)  
[origin: WO2022079315A1] A parapharmaceutical or pharmaceutical composition administrable to living beings, in particular to human beings, comprising at least one endoribonuclease enzyme chosen from the EC 3.1.30 and EC 3.1.31 classes, preferably in a content of from 10 to 1000 U/ml, preferably 50 to 500 U/ml, preferably from 100 to 500 U/ml, for use in a curative or preventive treatment for dermatological infections or for infections which develop on superficial or deep burns and wounds.

IPC 8 full level  
**A61K 38/46** (2006.01); **A61K 8/66** (2006.01); **A61K 38/14** (2006.01); **A61K 38/48** (2006.01); **A61K 38/54** (2006.01); **A61K 45/06** (2006.01); **A61L 2/00** (2006.01); **A61L 12/08** (2006.01); **A61P 31/04** (2006.01); **A61P 41/00** (2006.01)

CPC (source: EP US)  
**A01N 63/50** (2020.01 - US); **A01P 1/00** (2021.08 - US); **A61K 8/65** (2013.01 - US); **A61K 8/66** (2013.01 - EP); **A61K 38/14** (2013.01 - EP); **A61K 38/44** (2013.01 - US); **A61K 38/465** (2013.01 - EP US); **A61K 38/47** (2013.01 - US); **A61K 38/48** (2013.01 - US); **A61K 38/482** (2013.01 - EP US); **A61K 38/54** (2013.01 - EP); **A61K 45/06** (2013.01 - EP US); **A61P 31/04** (2017.12 - EP US); **A61P 41/00** (2017.12 - EP); **A61Q 3/00** (2013.01 - US); **A61Q 11/00** (2013.01 - EP US); **A61Q 17/005** (2013.01 - EP); **A61Q 19/008** (2013.01 - EP); **C12Y 301/30002** (2013.01 - EP); **C12Y 301/31001** (2013.01 - EP); **C12Y 302/01052** (2013.01 - EP); **C12Y 304/21062** (2013.01 - EP); **C12Y 406/01** (2013.01 - EP); **C12R 2001/43** (2021.05 - EP)

C-Set (source: EP)  
1. **A61K 38/465 + A61K 2300/00**  
2. **A61K 38/14 + A61K 2300/00**  
3. **A61K 38/482 + A61K 2300/00**

Citation (search report)  
See references of WO 2022079315A1

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)  
BA ME

Designated validation state (EPC)  
KH MA MD TN

DOCDB simple family (publication)  
**WO 2022079315 A1 20220421**; BE 1028712 A1 20220511; BE 1028712 B1 20220518; EP 4228678 A1 20230823; US 2023390366 A1 20231207

DOCDB simple family (application)  
**EP 2021078824 W 20211018**; BE 202005726 A 20201016; EP 21797993 A 20211018; US 202118249182 A 20211018